Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges

Table 1

Ongoing or recently completed clinical trials of a few liposomal nanoformulations used for cancer chemotherapy∗.

Trade name/composition	Indication	Phase	Stage
PEGylated Liposomal Doxorubicin	AIDS-associated non-Hodgkin’s lymphoma	I	Completed
Doxil/CAELYX Liposomal Doxorubicin	Malignant female reproductive system neoplasm, Ovarian cancer	I	Active
Doxil Liposomal Doxorubicin	Resistant solid malignancies	I	Completed
Liposomal Cytarabine	Central nervous system malignancies,; Stage IV breast cancer	II	Active
Liposomal Entrapped Paclitaxel Easy to Use (LEP-ETU)	Advanced cancer	I	Completed
Liposomal Daunorubicin	Hematologic cancer,; Chronic myelomonocytic leukemia; previously treated Myelodysplastic syndromes and; recurrent adult Acute myeloid leukemia	II	Completed
BLP25 Liposome Vaccine	Lung neoplasms; Non-small-cell lung carcinoma	II	Completed
CPX-351; Liposomal Cytarabine-Daunorubicin	Acute myeloid leukemia	I	Active
Liposomal Vincristine	Acute lymphoblastic leukemia	II	Active
Liposomal LE-SN38	Advanced cancer	I	Completed
IHL-305; Irinotecan Liposome Injection	Advanced solid tumours	I	Active
Liposome Encapsulated Mitoxantrone (LEM)	Advanced cancer	I	Completed
Liposomal Encapsulated Docetaxel (LE-DT)	Advanced solid tumours	I	Completed

∗Data retrieved from US National Institutes of Health website (http://clinicaltrials.gov/) on August 21, 2013.